Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Voriconazole

Research Leaders

5 sponsors active, led by The University of Queensland

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT01686607CompletedPrimary

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

NCT02968134Phase 4CompletedPrimary

Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients

NCT00721578CompletedPrimary

A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections

Showing all 3 trials

Research Network

Common Treatments

  • Voriconazole1
  • Other Parenteral Antifungal Drugs1
  • Parenteral Micafungin Application1
  • Posaconazole1

Active Sponsors

  • The University of Queensland1
  • Pfizer1
  • Royal Brisbane and Women's Hospital1
  • Astellas Pharma Europe B.V.1
  • World Health Information Science Consultants, LLC1

Top Investigators

Activity Timeline